Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Allred Capital Management LLC

Allred Capital Management LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,814 shares of the company’s stock after acquiring an additional 287 shares during the period. Merck & Co., Inc. comprises 1.1% of Allred Capital Management LLC’s holdings, making the stock its 19th largest position. Allred Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,892,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Investors Asset Management of Georgia Inc. GA ADV grew its holdings in Merck & Co., Inc. by 8.8% during the third quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 19,777 shares of the company’s stock worth $1,641,000 after acquiring an additional 1,600 shares during the period. Schneider Downs Wealth Management Advisors LP purchased a new position in Merck & Co., Inc. during the third quarter worth approximately $247,000. Strategic Investment Advisors MI boosted its position in Merck & Co., Inc. by 45.5% during the third quarter. Strategic Investment Advisors MI now owns 10,884 shares of the company’s stock worth $903,000 after purchasing an additional 3,402 shares in the last quarter. CRA Financial Services LLC boosted its position in Merck & Co., Inc. by 34.1% during the third quarter. CRA Financial Services LLC now owns 10,919 shares of the company’s stock worth $906,000 after purchasing an additional 2,776 shares in the last quarter. Finally, Paulson Wealth Management Inc. boosted its position in Merck & Co., Inc. by 5.9% during the third quarter. Paulson Wealth Management Inc. now owns 5,081 shares of the company’s stock worth $421,000 after purchasing an additional 281 shares in the last quarter. 73.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Merck & Co., Inc. stock opened at $79.83 on Friday. Merck & Co., Inc. has a one year low of $65.25 and a one year high of $92.64. The company has a market cap of $201.91 billion, a price-to-earnings ratio of 19.47, a PEG ratio of 2.10 and a beta of 0.43. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.32. The business’s 50 day moving average price is $83.27 and its 200 day moving average price is $80.42.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The firm had revenue of $10.87 billion for the quarter, compared to the consensus estimate of $10.52 billion. During the same quarter last year, the business posted $1.30 earnings per share. The firm’s revenue was down 7.6% compared to the same quarter last year. On average, analysts predict that Merck & Co., Inc. will post 5.68 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.61 per share. The ex-dividend date was Monday, September 14th. This represents a $2.44 dividend on an annualized basis and a yield of 3.06%. Merck & Co., Inc.’s payout ratio is 47.01%.

A number of equities analysts have issued reports on MRK shares. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a research report on Tuesday, September 22nd. JPMorgan Chase & Co. raised their target price on Merck & Co., Inc. from $98.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Thursday, October 1st. SVB Leerink raised their target price on Merck & Co., Inc. from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Finally, Goldman Sachs Group upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and raised their target price for the company from $91.00 to $105.00 in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $95.08.

In other Merck & Co., Inc. news, CFO Robert M. Davis sold 251,273 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $81.03, for a total transaction of $20,360,651.19. Following the completion of the sale, the chief financial officer now owns 422,329 shares of the company’s stock, valued at $34,221,318.87. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sanat Chattopadhyay sold 10,380 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $83.01, for a total value of $861,643.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 280,529 shares of company stock worth $22,761,633. 0.28% of the stock is currently owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Insider Trading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.